Companies › Zhaoke (Guangzhou) Ophthalmology Pharmaceutical
4 active drug programs in 34 registered trials: 15 Phase 2, 13 Phase 3, 4 Phase 4, 2 Phase 1; Ophthalmology, Gastroenterology, Other, Cardiovascular.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia; Achalasia; Progressive Myopia; Focus on Axial Length … | – |
| Cyclosporine Cyclophilin A modulator | PPIA | Phase 3 | Moderate to Severe Dry Eye; Meibomian Gland Dysfunction (MGD); Alopecia Areata(AA); Primary Autoimmune Hemolytic Anemia … | – |
| BRIMOCHOL PF eye drops Combined alpha-2A adrenergic agonist and muscarinic M3 receptor agonist | ADRA2A, M3 | Phase 2 | Presbyopia | – |
| CARBACHOL PF eye drops Muscarinic M3 receptor agonist (cholinergic miotic) | M3 | Phase 2 | Presbyopia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06209281 | Atropine | Phase 3 | Myopia | Ophthalmology | Aug 2023 |
| NCT06209281 | Atropine | Phase 3 | Myopia | Ophthalmology | Aug 2023 |
| NCT03140358 | Atropine | Phase 3 | Myopia | Ophthalmology | Dec 2024 |
| NCT06209320 | Atropine | Phase 3 | Myopia | Ophthalmology | Mar 2025 |
| NCT06209320 | Atropine | Phase 3 | Myopia | Ophthalmology | Mar 2025 |
| NCT06431841 | Atropine | Phase 4 | Myopia | Ophthalmology | Jun 2025 |
| NCT06948357 | BRIMOCHOL PF eye drops | Phase 2 | Presbyopia | Ophthalmology | Sep 2025 |
| NCT06948357 | CARBACHOL PF eye drops | Phase 2 | Presbyopia | Ophthalmology | Sep 2025 |
| NCT06766357 | Cyclosporine | Phase 3 | Moderate to Severe Dry Eye | Ophthalmology | Feb 2026 |
| NCT06523504 | Atropine | Phase 1 | Myopia | Ophthalmology | Mar 2026 |
| NCT06523504 | Atropine | Phase 1 | Myopia | Ophthalmology | Mar 2026 |
| NCT07456488 | Atropine | Phase 2 | Focus on Axial Length | Other | Apr 2026 |
| NCT06200194 | Atropine | Phase 2 | Myopia | Ophthalmology | Jul 2026 |
| NCT07816224 | Atropine | Phase 2 | Epiphora | Ophthalmology | Nov 2026 |
| NCT05057468 | Cyclosporine | Phase 3 | Primary Autoimmune Hemolytic Anemia | Hematology | Nov 2026 |
| NCT06708156 | Atropine | Phase 3 | Myopia | Ophthalmology | Dec 2026 |
| NCT06708156 | Atropine | Phase 3 | Myopia | Ophthalmology | Dec 2026 |
| NCT07224529 | Cyclosporine | Phase 4 | Meibomian Gland Dysfunction (MGD) | Ophthalmology | Feb 2027 |
| NCT05946772 | Cyclosporine | Phase 2 | Takotsubo Cardiomyopathy | Cardiovascular | Feb 2027 |
| NCT00544115 | Cyclosporine | Phase 2 | Chronic Myeloproliferative Disorders | Oncology | Mar 2027 |
| NCT07381556 | Cyclosporine | Phase 4 | Alopecia Areata(AA) | Immunology | Nov 2027 |
| NCT03865160 | Atropine | Phase 2 | Myopia, Progressive | Ophthalmology | Nov 2027 |
| NCT03865160 | Atropine | Phase 2 | Myopia, Progressive | Ophthalmology | Nov 2027 |
| NCT05153070 | Cyclosporine | Phase 2 | Type 1 Diabetes | Metabolic and endocrine | Nov 2027 |
| NCT00977977 | Cyclosporine | Phase 2 | Nephrotic Syndrome | Genitourinary | Dec 2027 |
| NCT05815784 | Atropine | Phase 2 | Myopia | Ophthalmology | Jan 2028 |
| NCT07567040 | Atropine | Phase 3 | Myopia | Ophthalmology | May 2028 |
| NCT04641702 | Atropine | Phase 4 | Achalasia | Gastroenterology | Dec 2028 |
| NCT05667454 | Atropine | Phase 3 | Progressive Myopia | Ophthalmology | Apr 2029 |
| NCT05667454 | Atropine | Phase 3 | Progressive Myopia | Ophthalmology | Apr 2029 |
| NCT01624805 | Cyclosporine | Phase 2 | Aplastic Anemia | Hematology | Jun 2029 |
| NCT07095894 | Atropine | Phase 3 | Myopia | Ophthalmology | Jul 2029 |
| NCT07874490 | Cyclosporine | Phase 2 | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Oncology | Dec 2030 |
| NCT04304820 | Cyclosporine | Phase 2 | Severe Aplastic Anemia | Hematology | Dec 2033 |
Bristol-Myers Squibb AstraZeneca Ocus Innovation Ireland GSK Novartis BioTheraVision Chiesi Farmaceutici Anavex Life Sciences ACADIA Pharmaceuticals NSC-Therapeutics
Ocus Innovation Ireland BioTheraVision Laboratoires Thea Opus Genetics Huons
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.